|
|
|
| Final Program >
March 6th
Objectives of the Symposium
ConferenceChairwoman:
Which are the current evidence that support the benefits of drug eluting stents well beyond controlled studies?
Live case # 1Strategies for revascularization of lesions in bifurcationsCoordinator:
Panelists:
Operator:
Curricular updatingChairman:
Which is the best strategy, in 2008, to treat lesions in bifurcations?
Dedicated stents for bifurcations: a promising future or still a far away dream?
Questions and answers
Coffee break
Live case # 2Complex multiartery diseaseCoordinator:
Mini-conferenceChairman:
Late thrombosis of drug eluting stents: what are the conclusions and current advice to elevate late safety?
Percutaneous correction of the aortic valve: where are we now and what are the future perspectives?
Questions and answers
Lunch
Live case # 3Chronic occlusionsCoordenador:
Curricular updatingChairman:
New interventionist strategies for the approach of chronic occlusion: when to choose the anterograde way, retrograde way or use both?
Wires or dedicated devices: learning how to choose the most adequate material and which are the existing options.
Questions and answers
Coffee break
Live case # 4Multi-vessel disease with moderate dtenosisCoordinator:
Recommendations and guidelinesChairman:
What is the clinical impact of complete revascularization of the myocardium: should we try to recanalyze all chronic occlusions?
Implant of drug eluting stents after opening an occlusion: which is the recommendation for the choosing of devices, length and late safety issues.
Questions and answers
Live case # 5Multi-vessel coronary disease in diabeticsCoordinator:
Future perspectives: Drug-eluting stentsChairman:
Late results and future projections for stents with Zotarolimus and Everolimus.
Perspectives with the new eluting platforms of Sirolimus, stents with Biolimus, Novolimus and Miolimus.
Questions and answers
End of the first day |